Moxifloxacin Fresenius Kabi (Moxifloxacin Hydrochloride)

Moxifloxacin is a broad‑spectrum fluoroquinolone used to treat infections caused by susceptible bacteria.

• Community‑acquired pneumonia: achieves clinical cure by targeting typical and atypical respiratory pathogens.
• Acute bacterial sinusitis: reduces symptom duration and bacterial load in sinus mucosa.
• Acute bacterial exacerbation of chronic bronchitis: improves airflow and resolves infection.
• Skin and skin‑structure infections: eradicates Gram‑positive and Gram‑negative organisms in soft‑tissue infections.
• Intra‑abdominal infections: provides coverage for mixed aerobic and anaerobic bacteria in complicated abdominal cases.

• Moxifloxacin inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA replication, transcription, and repair. By stabilizing the enzyme‑DNA complex, it prevents the resealing of DNA breaks, leading to bacterial cell death. This dual inhibition expands its activity against both Gram‑positive and Gram‑negative organisms, including atypical pathogens.

Moxifloxacin may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Diarrhea: loose stools, sometimes watery.
• Headache: transient cranial discomfort.
• Rash: erythematous skin lesions.
• Elevated liver enzymes: transient increase in ALT/AST.
• Taste disturbance: altered perception of flavors.

Serious or Rare Side Effects

• Tendon rupture: especially Achilles, may occur during or after therapy.
• QT interval prolongation: risk of ventricular arrhythmias.
• Clostridioides difficile infection: severe colitis following disruption of gut flora.
• Severe hypersensitivity: anaphylaxis or Stevens‑Johnson syndrome.
• Hepatic failure: rare but potentially life‑threatening liver injury.

Moxifloxacin requires careful assessment before use to minimise risks.

• Renal impairment: monitor renal function and adjust therapy as needed.
• Hepatic impairment: evaluate liver enzymes regularly during treatment.
• QT prolongation risk: avoid in patients with known cardiac arrhythmias or electrolyte disturbances.
• Concomitant corticosteroids: increase risk of tendon injury; use with caution.
• Pregnancy and lactation: prescribe only when benefits outweigh potential fetal or neonatal risks.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Moxifloxacin can interact with several drug classes, altering efficacy or safety.

Major Interactions (Avoid)

• Antacids containing magnesium or aluminum: reduce absorption; separate administration by at least 2 hours.
• Drugs that prolong QT interval (e.g., macrolides, antiarrhythmics): increase risk of cardiac arrhythmias.
• Warfarin: may enhance anticoagulant effect, requiring INR monitoring.

Moderate Interactions (Monitor Closely)

• NSAIDs: may increase risk of central nervous system stimulation.
• Oral contraceptives: possible reduction in contraceptive efficacy; advise additional non‑hormonal methods.
• Diabetic agents: heightened risk of hypoglycemia; monitor blood glucose levels.